Unlock instant, AI-driven research and patent intelligence for your innovation.

Cadherin-17-specific antibodies and cytotoxic cells for cancer therapy

A cadherin, cytotoxicity technology applied in the field of cancer immunotherapy, which can solve the problems of limited expression and no observed partial or complete response

Active Publication Date: 2021-11-05
嘉立医疗科技(广州)有限公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

GPC3 (glypican-3) is highly expressed in HCC but limited in normal tissues (63.6% vs. 9.2%)
Unfortunately, no partial or complete responses were observed in a Phase 1 clinical trial study of the anti-GPC3 mAb GC33 developed by Roche subsidiary Chugai

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cadherin-17-specific antibodies and cytotoxic cells for cancer therapy
  • Cadherin-17-specific antibodies and cytotoxic cells for cancer therapy
  • Cadherin-17-specific antibodies and cytotoxic cells for cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0136] Example 1 Research Design and Methods

[0137] An orthotopic tumor xenograft model was used to test the effect of Lic5 alone or in combination with cisplatin or epirubicin on tumor growth inhibition and animal survival. Human HCC cell lines MHCC97-L (97L) and PLC / PRF / 5 (PLC) were used. Lic5, cisplatin, and epirubicin treatment alone inhibited the growth of cultured HCC cells using a cell proliferation assay, while a more significant reduction was observed when either cisplatin or epirubicin was used together with Lic5. Similar growth inhibition trends were observed when the same experimental group was applied to orthotopic tumor-bearing nude mice.

[0138] Treatment with Lic5 enhanced the survival of orthotopic tumor-bearing nude mice when compared to controls. The combined Lic5 and epirubicin group produced the best survival among all experimental groups. For the next stage of antibody humanization, the complementarity determining regions (CDRs) on the variable re...

example 3

[0141] Example 3 In Vivo Cell Proliferation Assay

[0142] A predetermined number of 97L and PLC cells were seeded onto 96-well culture plates for 1 day. Mouse IgG (Sigma-Aldrich, St. Louis, MO, USA) at 150 μg / ml was used as a control for Lic5. After treatment, proliferation of treated cells was measured using Cell Proliferation Kit I (Roche, Indianapolis, IN, USA) as described above. Briefly, treated cells were used to incubate MTT reagent for 4 hours. The colorimetric signal was then measured after addition of 10% SDS. To confirm the results an independent cell proliferation MTT assay was performed at least twice.

example 4

[0143] Example 4 Orthotopic Xenograft Model

[0144] Male nude mice were obtained from the Laboratory Animal Unit of the University of Hong Kong, Hong Kong. Animals were housed in individually ventilated cages on a 12 h light / 12 h dark cycle and had free access to autoclaved water and food. The animal experiments performed in this study were approved by the committee that permits the use of live animals in our Faculty for Teaching and Research (CULATR). To allow in vivo visualization of growing orthotopic liver tumors, a pre-established luciferase-labeled 97L cell line was used. 5x106 luciferase-labeled 97L cells were injected subcutaneously into nude mice to allow subcutaneous tumor growth. These subcutaneous tumors were harvested when they reached 200-300 mm3 in size and used as tumor inoculations to establish orthotopic liver tumors in isolated groups of nude mice following standard procedures. Five days after orthotopic tumor implantation, mice received the following ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Embodiments of the present disclosure relate to cadherin-17 specific antibodies and cytotoxic cells for cancer treatment. For example, the antibody may have specificity for cadherin-17 and comprise an amino acid sequence having at least 70% similarity to an amino acid sequence selected from SEQ ID NO: 1-21.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62,276,855, entitled "Cadherin-17-Specific Antibodies and Cytotoxic Cells for Cancer Therapy," filed January 9, 2016, the entire contents of which are incorporated herein by reference Incorporated into this article. technical field [0003] The present disclosure relates generally to the technical field of cancer immunotherapy, and more specifically, to cadherin-17 specific antibodies and cytotoxic cells for cancer treatment. Background technique [0004] Despite recent advances in drug discovery and clinical imaging, cancer remains one of the deadliest diseases of humanity. Our understanding of how tumors arise, survive stress, colonize / metastasize to distant organs and sites, and become resistant to drugs is still limited. The American Cancer Society estimated that there were 1.6 million new cases of cancer in the United States in 2014, with no ap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395C07K16/18C12N15/12
CPCC07K16/28C07K16/2809A61K45/06A61P35/00C07K2317/24C07K2317/31C07K2317/622C07K2317/77C07K2317/73C07K2317/92C07K2319/33C07K2319/03A61K2039/505C07K14/7051C12N5/0636C12N5/0646C12N2510/00A61K39/3955A61K2300/00A61K39/395C07K16/2839C12N15/11
Inventor 唐纳德·E·斯汤顿约翰·穆恩钦·卢克李志杰
Owner 嘉立医疗科技(广州)有限公司